Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METRA vs METROGEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metformin primarily decreases hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), leading to reduced gluconeogenesis and increased peripheral glucose uptake.
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
Type 2 diabetes mellitus,Polycystic ovary syndrome (off-label)
Topical treatment of inflammatory papules and pustules of rosacea,Treatment of bacterial vaginosis (off-label),Treatment of acne vulgaris (off-label)
Adults: 20 mg orally once daily.
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
Terminal elimination half-life: 3-7 hours (mean 4.5 hours). Increased to 8-15 hours in moderate-to-severe renal impairment (Cr Cl <30 m L/min).
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
Metformin is excreted unchanged in urine; does not undergo hepatic metabolism or cytochrome P450 metabolism.
Hepatic via glucuronidation and oxidation; metabolites excreted renally.
Primarily renal: 70-80% unchanged drug via glomerular filtration and active tubular secretion; 15-20% biliary/fecal as metabolites.
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein.
Less than 20%; albumin.
Vd: 1.5-2.5 L/kg (mean 2.0 L/kg). Extensive tissue distribution; crosses blood-brain barrier and placenta.
0.25-0.85 L/kg; extensive tissue distribution including CSF.
Oral: 60-75% (due to first-pass metabolism); intramuscular: 90-100%; topical: 10-20% (formulation-dependent).
Topical: minimal systemic absorption (2-4%); oral: 80-100%; intravenous: 100%.
e GFR ≥30 m L/min: no adjustment; e GFR <30 m L/min: 10 mg once daily.
No dose adjustment required for topical or intravaginal use; systemic absorption is minimal.
Child-Pugh A: no adjustment; Child-Pugh B: 10 mg once daily; Child-Pugh C: not recommended.
No dose adjustment required; use with caution in severe hepatic impairment due to potential for increased systemic exposure.
Weight ≥30 kg: 20 mg once daily; weight <30 kg: 10 mg once daily.
Topical 1% gel: apply twice daily for children ≥12 years; safety and efficacy for rosacea in children <12 not established.
≥65 years: initial dose 10 mg once daily, titrate as tolerated.
No specific dose adjustment; use same dosing as adults; monitor for local adverse effects due to thinner skin.
Lactic acidosis: Metformin use has been associated with lactic acidosis, a rare but serious metabolic complication. Risk factors include renal impairment, concomitant use of certain drugs, age ≥65 years, and hepatic disease.
No FDA black box warning.
Lactic acidosis risk, impaired renal function (monitor e GFR), vitamin B12 deficiency, acute metabolic acidosis, perioperative use, and concurrent iodinated contrast agents.
Avoid unnecessary prolonged use; may cause peripheral neuropathy with chronic use; discontinue if neurological symptoms occur; photosensitivity reactions; avoid sun exposure.
Severe renal impairment (e GFR <30 m L/min/1.73 m²), acute metabolic acidosis, severe hepatic disease, and hypersensitivity to metformin.
Hypersensitivity to metronidazole or any component of the formulation; concurrent disulfiram use; history of alcoholic beverage consumption during therapy.
Avoid high-sodium foods as they may counteract the antihypertensive effect. Consumption of potassium-rich foods (e.g., bananas, oranges) is not restricted unless hypokalemia develops, but monitor potassium levels. Grapefruit juice may increase metolazone absorption; avoid concurrent use. Limit alcohol intake as it may enhance hypotensive effects.
No significant food interactions specific to topical metronidazole; however, systemic metronidazole has alcohol interaction (disulfiram-like reaction), so patients should avoid alcohol while using topical formulation? Although topical absorption is minimal, caution is advised. No specific dietary restrictions.
METRA is contraindicated in pregnancy due to documented teratogenicity, including neural tube defects, cardiovascular malformations, and craniofacial abnormalities in first trimester. Second and third trimester exposure may cause low birth weight and transient neonatal metabolic disturbances. Use effective contraception during treatment.
Metronidazole crosses the placenta. First trimester: avoid unless essential; second/third trimester: no increased risk of major malformations in large cohort studies; potential neurodevelopmental risks unclear.
METRA is excreted into human breast milk with an M/P ratio of approximately 0.8 to 1.2. Due to potential adverse effects in nursing infants, such as immunosuppression and growth delay, breastfeeding is not recommended during therapy and for 12 months after last dose.
Excreted in breast milk; M/P ratio ~1.0; American Academy of Pediatrics considers compatible; delay breastfeeding 12-24h after IV dose.
No dosing adjustments are recommended because METRA is contraindicated in pregnancy. In the rare event of inadvertent use during pregnancy, immediate discontinuation is required. Pharmacokinetic changes in pregnancy (increased clearance, reduced protein binding) do not apply as therapy must be ceased.
No dose adjustment required for topical METROGEL; systemic absorption negligible.
METRA is a brand name for metolazone, a thiazide-like diuretic. Use with caution in severe renal impairment (e GFR <20 m L/min) as effectiveness diminishes. Monitor for hypokalemia, especially when used with loop diuretics. Do not use in hepatic coma or pre-coma.
Metro Gel (metronidazole topical gel) is first-line for rosacea papules/pustules; avoid use in ocular rosacea as it can worsen symptoms. It is not effective for erythematotelangiectatic rosacea. For bacterial vaginosis, oral or intravaginal metronidazole is preferred; Metro Gel is not FDA-approved for vaginosis. In acne, it is less effective than topical antibiotics like clindamycin. Warn patients about rare metallic taste if gel is applied near lips.
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,May cause dizziness or lightheadedness due to blood pressure changes; rise slowly from sitting or lying positions.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,Report signs of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, or extreme thirst.,Do not consume alcohol or take other blood pressure medications without consulting your doctor.
Apply a thin layer to affected areas once or twice daily as directed; avoid contact with eyes, mouth, and mucous membranes.,Do not use cosmetics or other skin products on treated areas unless approved by your doctor.,Avoid sun exposure; use sunscreen and protective clothing as metronidazole may increase sensitivity to UV light.,Report any signs of allergic reaction (rash, itching, swelling) or worsening skin redness.,If accidental ingestion occurs, seek medical attention immediately; metronidazole can cause systemic side effects.,Do not use during pregnancy (especially first trimester) or while breastfeeding without consulting your healthcare provider.
"Concurrent use of Phenmetrazine, a sympathomimetic amine with central nervous system stimulant activity, and Isoxsuprine, a beta-adrenergic receptor agonist with peripheral vasodilatory effects, may result in additive stimulation of the cardiovascular system. This can lead to synergistic increases in heart rate, myocardial contractility, and blood pressure, potentially precipitating hypertensive crisis, tachycardia, arrhythmias, or myocardial ischemia. Clinically, this interaction poses significant risks for patients with underlying cardiovascular disease, and careful monitoring is essential if concomitant use is unavoidable."
"The combination of Phenmetrazine, a sympathomimetic appetite suppressant, with Oxymetazoline, a direct-acting alpha-adrenergic agonist, can lead to additive vasoconstriction and hypertensive effects. This interaction may precipitate a hypertensive crisis, especially in patients with underlying cardiovascular disease, and can result in adverse outcomes such as myocardial ischemia, stroke, or arrhythmias. Concurrent use should be avoided due to the potential for severe cardiovascular adverse events."
"Amphetamine and phenmetrazine are both central nervous system (CNS) stimulants that increase synaptic norepinephrine and dopamine by promoting release and blocking reuptake. Concurrent use synergistically amplifies adrenergic and dopaminergic signaling, leading to excessive CNS stimulation and cardiovascular strain. This can manifest as severe hypertension, tachyarrhythmia, hyperthermia, agitation, serotonin syndrome-like symptoms, and potentially life-threatening events such as stroke or myocardial infarction."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METRA vs METROGEL, answered by our medical review team.
METRA is a Antibiotic (Nitroimidazole) that works by Metformin primarily decreases hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK), leading to reduced gluconeogenesis and increased peripheral glucose uptake.. METROGEL is a Antibiotic (Nitroimidazole) that works by Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METRA and METROGEL depend on the specific clinical indication. These are both Antibiotic (Nitroimidazole) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METRA is: Adults: 20 mg orally once daily.. The standard adult dose of METROGEL is: Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METRA and METROGEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METRA is classified as Category C. METRA is contraindicated in pregnancy due to documented teratogenicity, including neural tube defects, cardiovascular malformations, and craniofacial abnormalities in first trimest. METROGEL is classified as Category C. Metronidazole crosses the placenta. First trimester: avoid unless essential; second/third trimester: no increased risk of major malformations in large cohort studies; potential neu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.